Back to Registry

Semax

Also known as: ACTH(4-7)-PGP, Heptapeptide Semax

Research Only

Molecular Formula

C37 H51 N9 O10 S

Molecular Weight

813.92 Da

Half-Life

1–2 hours (plasma elimination); biological efficacy persists up to 24 hours

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Clinical Applications & Evidence

Mechanism of Action

Semax initiates a pleiotropic neurobiological cascade. It significantly upregulates the mRNA expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), alongside their respective Trk receptors. Concurrently, the peptide modulates the dopaminergic and serotonergic neurotransmitter systems to enhance executive function and mood. During ischemic or traumatic neural events, Semax exerts a 'transcriptomic compensation effect,' actively suppressing pro-inflammatory cytokine and apoptotic genes (MMP-9, c-Fos, JNK) while simultaneously activating genes responsible for neurotransmission and vascular repair. Additionally, Semax exhibits anti-amyloidogenic properties by strongly chelating copper (Cu²⁺) ions, thereby inhibiting amyloid-beta fibrillogenesis.

Investigated Uses

  • Cognitive enhancement and memory
  • Ischemic stroke recovery (approved in Russia)
  • ADHD and attention disorders
  • Optic nerve disease
  • Neuroprotection in neurodegeneration
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

Research Only

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

Nasal irritationMild headache (rare)Hair loss at high doses (rare, reversible)

Contraindications

  • Pregnancy
  • Acute psychosis
  • Known allergy to ACTH derivatives

Drug Interactions

  • May potentiate stimulant medications
  • Synergistic with Selank

Citations & Clinical Trials